Latest
industry research report on: Global Antidiabetics Market : Industry
Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth,
Segmentation, Parameters, Forecasts
The anti-diabetics market
includes drugs, which are used for treatment of diabetes mellitus and
are also known as oral hypoglycemic/antihyperglycemic agents. The
anti-diabetics market has grown tremendously in recent years with
increasing prevalence of diabetes mellitus. Thus, systemic therapies
for diabetes have become the focal point of attention due to the
burgeoning diabetic population size, with diabetes affecting middle
age groups and children across all income groups globally.
Complete Report Details @
https://www.marketresearchreports.biz/reports/1353563/antidiabetics-global-industry-analysis-market-research-reports
The
anti-diabetics market has been segmented based on type of drug class
into biguanides (metformin), sulfonylureas (glimepiride),
meglitinides (repaglinide), thiazolidinediones (pioglitazone),
dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and
?-glucosidase inhibitors (acarbose).
Among
these drug classes, Biguanides act directly against insulin
resistance. Sulfonylureas (SUs) were the earliest drug classes in the
market for treatment of diabetes and have a significant market
presence. ?-glucosidase inhibitors delay postprandial glucose
absorption by hydrolysis of disaccharide is into monosaccharide’s
in the small intestine. Meglitinides are prandial insulin releasers
that stimulate rapid insulin secretion. The thiazolidinediones are
insulin-sensitizing drugs, which improve whole-body insulin
sensitivity through gene regulation. DPP-IV inhibitors make a
significant impact on glucose tolerance and make lasting improvements
in the health outcomes of diabetic patients.
Some
of the major drivers and opportunities for growth of this market
include drug combinations of several agents such as sitagliptin and
metformin and other drug combinations that are in different stages of
clinical and pipeline development. Increase in the prevalence of
diabetes and new product launches by major pharmaceutical companies
re some of the key drivers for growth in this market. In 2015,
Boehringer Ingelheim GmbH launched two new drugs (Synjardy &
Glyxambi)for treatment of diabetes mellitus type II.
Some
of the key opportunities for the antidiabetics include a strong
pipeline for antidiabetics and entry of new players in the market,
for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg
received FDA approval in September 2015. Moreover, Boehringer
Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as
Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for
patients suffering from diabetes mellitus type II and high
cardiovascular risk.
Have Any Query? Ask Our Expert @
https://www.marketresearchreports.biz/sample/enquiryBuy/1353563
However, despite the
availability of numerous branded antidiabetic drugs, many of these
drugs have lost patent protection. In the wake of huge pressures from
government and regulatory authorities, which have banned top selling
drugs in various countries, in order to promote generic drugs at
lower costs for diabetic patients. For instance, Mankind Pharma,
launched anti-diabeticDynaglipt (Teneligliptin) under the drug class
DPP-4 inhibitors in November 2015 in India targeting the middle to
low income diabetic patient population.
As a result, the volume of
antidiabetics is expected to shift to first generation drugs and
other generic drugs in the market. Moreover, there is a huge unmet
medical need for antidiabetics that can treat multiple chronic
disorderscoexisting with diabetessuch as cardiovascular diseases,
dyslipidemia, hypertension etc. Another major restraint in the
antidiabetics market is reduction in the efficacy of drugs over a
period and canlead to other health complications.
Some of the major players in
the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli
Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck &
Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva
Pharmaceutical Industries Ltd.
This research report analyzes
this market on the basis of its market segments, major geographies,
and current market trends. This report provides comprehensive
analysis of
Market growth drivers
Factors limiting market
growth
Current market trends
Market structure
Market projections for
upcoming years
This report is a complete study
of current trends in the market, industry growth drivers, and
restraints. It provides market projections for the coming years. It
includes analysis of recent developments in technology, Porter’s
five force model analysis and detailed profiles of top industry
players. The report also includes a review of micro and macro factors
essential for the existing market players and new entrants along with
detailed value chain analysis.
Reasons for Buying this
Report
This report provides
pin-point analysis for changing competitive dynamics
It provides a forward
looking perspective on different factors driving or restraining
market growth
It provides a six-year
forecast assessed on the basis of how the market is predicted to grow
It helps in understanding
the key product segments and their future
It provides pin point
analysis of changing competition dynamics and keeps you ahead of
competitors
It helps in making informed
business decisions by having complete insights of market and by
making in-depth analysis of market segments
It provides distinctive
graphics and exemplified SWOT analysis of major market segments
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment